Although the upstream mechanism for WEE1 activation in atherosclerosis needs to be further investigated, our findings point out new directions to broaden the clinical applications for WEE1 inhibitor MK1775 in cardiovascular diseases and even other inflammatory diseases. Here, WEE1 is linked to atherosclerosis.